Sydney, Jan 16, 2026, 16:50 AEDT — After-hours
- CSL finished a touch up but failed to keep pace with the broader market’s late-week gains.
- The stock remains far from its 12-month peak following last year’s downward revision in outlook.
- Attention shifts to CSL’s half-year results for February, with investors hunting for guidance and insights on Seqirus.
CSL Limited (ASX:CSL) shares ended Friday 0.14% higher, closing at A$175.53. The stock fluctuated between A$174.35 and A$176.03 during the session, with roughly 1.07 million shares traded. The S&P/ASX 200 finished the day up 0.48%, settling at 8,903.90.
The move is significant since CSL is a key player in Australian healthcare portfolios, with its stock attempting to find footing before the upcoming earnings report. Investors remain alert for signs the company can bounce back after a tough second half in 2025.
Despite gains this week, CSL’s shares are still well under their 52-week peak of A$280.43, hovering just above the 52-week low of A$168.29. The stock often swings sharply in response to updates on both its vaccine segment and its main plasma-derived therapies.
CSL’s half-year results loom as the next big event, scheduled for a webcast at 10 a.m. AEDT on Wednesday, Feb. 11.
The backdrop remains last year’s reset. At its October annual meeting, CSL lowered its fiscal 2026 revenue growth forecast to 2%–3%, down from 4%–5%, while trimming NPATA growth guidance to 4%–7% from 7%–10% (constant currency). CEO Paul McKenzie pointed to “a greater decline in influenza vaccination rates.” The company also said it would revisit the vaccine-unit demerger “when market conditions would support the maximisation of shareholder value.” Reuters
NPATA stands for net profit after tax and amortisation, a profit metric often used by Australian firms that excludes amortisation on acquired intangibles. “Constant currency” indicates results have been adjusted to eliminate the impact of exchange-rate fluctuations.
In the February report, investors will be watching closely for updates on the fiscal 2026 outlook, insights into plasma demand and collection costs, and any clearer guidance on the timing of the Seqirus separation.
The risk lies in weak U.S. flu vaccination rates dragging on through the northern-hemisphere season, continuing to weigh on the vaccine unit and capping any potential for a more positive outlook. Meanwhile, any new cost increases in plasma collection would be swiftly reflected in margins.
CSL is holding the market’s focus for the moment, though no fresh headlines have surfaced. All eyes now turn to Feb. 11, when the company reports half-year results and tackles queries on guidance and its vaccine operations.
